Nicotine & nicotine substitute manufacturer - BGP™ Group of Companies
 

Product: Nicotine Alkaloid 95%

 
Nicotine & nicotine substitute Products
NICOTINE SULPHATE 40%
NICOTINE ALKALOID 95%
NICOTINE USP/EP
NICOTINE BITARTRATE DIHYDRATE
NICOTINE POLACRILEX USP/EP15%
NICOTINE POLACRILEX USP/EP 20%
COTININE
CUPROUS CHLORIDE
POTASSIUM NITRITE

Nicotine Alkaloid 95%
Nicotine Alkaloid 95%
TEST SPECIFICATION
MOLECULAR FORMULA : C10H14N2
MOLECULAR WEIGHT : 162KG/KG MOLE
APPEARANCE : REDDISH BROWN LIQUID
ASSAY AS NICOTINE : 95% MIN. w/w
PH : 9 TO 11
Nicotine Alkaloid 95%
IDENTIFICATION
CAS 54-11-5
MF : C10H14N2
MW: 162
BP: 247 DEG. CEL. WITH DECOMPOSITION
APPEARANCE : COLORLESS OILY LIQUID
VAPOUR PRESSURE : 0.43 MM HG AT 20 DEG.CEL.
SOLUBILITY : IN ALCOHOL, ETHER, CHLOROFORM , BENZENE
CHEMICAL FAMILY : PYRIDINE
Nicotine Alkaloid 95% 
S-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE

1 METHYL-2(3-PYRIDYL) PYRROLIDONE

It is classified as an alkaloid in organic chemistry and is found as a chief alkaloid of tobacco plant (nicotiana tobacum) wherein it is present as a salt of malic or citric acid. Its concentration is highest in leaves of toabacco where it varies from 0.6 to 8 % depending upon the kind of tobacco

It is readily soluble in water and has an unpleasant smell unlike that of tobacco. It has a burning taste and is very poisonous. It turns brown on exposure to air due to bonding with oxygen.

Nicotine & nicotine alkaloid 95%

Used mainly as an insecticide and fumigant in some countries. It is a contact poison. It is totally decomposed over a time and does not leave any residue on plants where it is used.

In the manufacture of smoking cessation products like nicotine based chewing gums and patches. Here it is used in the form of nicotine polacrilex.

Can be used to manufacture nicotinic acid and thus a regenerable raw material can be used if produced from this source. Presently nicotinic acid is produced from beta picoline due to economical reasons.

As an ectoparasiticide. Has been used as an enthalmintic.

A lot of interest has been recently directed towards the therapeutic potential of nicotine because of two diseases namely parkinsons and alzhimers. These two diseases have some behavorial similarity but in contrast to alzihimers , parkinsonsism is related to the destruction of brain dopamine neurons wiht few changes in the nicotine receptor. Some researchers suggest that nicotine benefits in parkinson patient may be related to the drugs ability to shutdown (desensitize) dopamine neurons.


Go to MSDS Go To TOP
ResourcesSite Developed By Jinesys